Genetic Analysis Expands Global Reach in Q1 2025
Genetic Analysis reports strategic growth and international expansion in Q1 2025, despite a dip in sales.
Sammanfattning
Genetic Analysis shows strategic progress in Q1 2025 with expanded global presence, improved EBITDA, and new market entries despite decreased sales.
The first quarter of 2025 marked a period of strategic progress and international reach for Genetic Analysis, as highlighted by CEO Ronny Hermansen. Despite a 27% decline in sales to NOK 2.4 million, the company demonstrated resilience through strategic partnerships and operational efficiencies.
The company's gross margin increased to 84%, a notable improvement from 77% in the same period last year. This improvement was attributed to a refined product mix and cost savings from manufacturing enhancements. The EBITDA also showed a positive trend, improving from NOK -4.5 million in Q1 2024 to NOK -3.5 million in Q1 2025, thanks to reduced R&D spending and optimized organizational structures.
Strategic collaborations played a crucial role in Genetic Analysis's Q1 performance. The extension of the distribution and logistics agreement with Diasorin for the GA-map® Dysbiosis Test in the DACH & Poland region, along with new entries into selected Baltic countries, underscores the company's commitment to global expansion.
A significant milestone was the launch of the GA-map® Dysbiosis Test in China, in partnership with Thalys Medical Technology Group. This move into the Chinese Consumer Health market marks a strategic entry into a high-growth region, with the test tailored to local demands and enhanced with mobile-based access and personalized recommendations.
Furthermore, the directed share issue of NOK 12.8 million in May 2025 signals strong shareholder confidence and provides capital to support ongoing collaborations, such as with Ferring Pharmaceuticals, and to explore new microbiome-related opportunities.
Leadership changes with the appointment of Morten Jurs as Chairman and Ove Öhman as a board member bring valuable expertise to guide future growth. These strategic moves position Genetic Analysis well for sustained progress in the competitive microbiome diagnostics market.
Given the strategic advancements and financial improvements, investors might consider holding their positions in Genetic Analysis. The company's focus on expanding its global footprint and enhancing operational efficiency suggests potential for future growth, despite the current sales dip.
Källa
Sammanfattning
Genetic Analysis, under CEO Ronny Hermansen, reported strategic progress and international expansion in Q1 2025. Operating income was NOK 4.0 million, with sales at NOK 2.4 million, a 27% decrease from the previous year due to inventory adjustments by partners. Despite lower sales, the gross margin improved to 84%, and cost-saving measures led to better EBITDA and reduced net loss compared to Q1 2024. The company launched the GA-map® Dysbiosis Test in China and announced a directed share issue of NOK 12.8 million to support collaborations, including with Ferring. Changes to the Board of Directors included appointing Morten Jurs as Chairman and Ove Öhman as a new member.
